Neurocrine Biosciences, Inc [NBIX] stock prices are up 0.42% to $107.69 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NBIX shares have gain 4.33% over the last week, with a monthly amount drifted -2.63%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neurocrine Biosciences, Inc [NASDAQ: NBIX] stock has seen the most recent analyst activity on April 15, 2025, when Needham upgraded its rating to a Buy but kept the price target unchanged to $138 for it. Previously, RBC Capital Mkts upgraded its rating to Outperform on April 14, 2025, and kept the price target unchanged to $137. On February 11, 2025, Deutsche Bank initiated with a Hold rating and assigned a price target of $138 on the stock. Piper Sandler upgraded its rating to a Overweight and raised its price target to $159 on August 29, 2024. Wells Fargo upgraded its rating to Overweight for this stock on April 24, 2024, and upped its price target to $170.
The stock price of Neurocrine Biosciences, Inc [NBIX] has been fluctuating between $84.23 and $157.98 over the past year. Currently, Wall Street analysts expect the stock to reach $159.5 within the next 12 months. Neurocrine Biosciences, Inc [NASDAQ: NBIX] shares were valued at $107.69 at the most recent close of the market. An investor can expect a potential return of 48.11% based on the average NBIX price forecast.
Analyzing the NBIX fundamentals
The Neurocrine Biosciences, Inc [NASDAQ:NBIX] reported sales of 2.36B for trailing twelve months, representing a surge of 21.84%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.25%, Pretax Profit Margin comes in at 0.21%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.09, Equity is 0.13 and Total Capital is 0.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 106.40 points at the first support level, and at 105.10 for the second support level. However, for the 1st resistance point, the stock is sitting at 108.48, and for the 2nd resistance point, it is at 109.27.
Ratios To Look Out For
It’s worth pointing out that Neurocrine Biosciences, Inc [NASDAQ:NBIX]’s Current Ratio is 3.40. Further, the Quick Ratio stands at 3.28, while the Cash Ratio is 0.46. Considering the valuation of this stock, the price to sales ratio is 4.52, the price to book ratio is 4.13 and price to earnings (TTM) ratio is 32.72.
Transactions by insiders
Recent insider trading involved Cooke Julie, Chief Human Resources Officer, that happened on Feb 13 ’25 when 1551.0 shares were sold. Director, GORMAN KEVIN CHARLES completed a deal on Feb 13 ’25 to sell 5844.0 shares. Meanwhile, Director SHERWIN STEPHEN A sold 13831.0 shares on Feb 13 ’25.
